Revvity (RVTY) Stock

Revvity's results for the third quarter show significant growth in their Diagnostics business, but there has been a drop in sales in the Life Sciences sector.

Revvity (RVTY) reported quarterly earnings of $1.28 per share, which is higher than the Zacks Consensus Estimate of $1.13 per share. This is an increase compared to earnings of $1.18 per share from the same period last year.

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) has announced its financial results for the third quarter ending September 29, 2024. The company reported earnings per share of $0.77, up from $0.08 during the same quarter last year. Additionally, GAAP revenue for this quarter was $684 million, compared to $671 million in the previous year, with an operating income of $98 million, rising from $69 million a year ago.

Revitty Incorporated (NYSE:RVTY) will hold its Q3 2024 earnings conference call on November 4, 2024, at 8:00 AM ET. The call will feature company leaders including Prahlad Singh, the CEO, and Max Krakowiak, the CFO, along with various participants from major financial institutions. The operator, Lydia, will welcome everyone to the call.

RVTY's results for the third quarter are expected to show good performance in the Diagnostics area, but the Life Sciences sector may continue to struggle in China.

RVTY has launched Transcribe AI, a tool that converts handwritten test request forms into digital format. This innovation speeds up workflows and minimizes mistakes in data entry.

Revvity's new solution for accurately typing the AD-related APOE gene may help evaluate a patient's risk of negative effects from new anti-amyloid treatments for Alzheimer's.

RVTY's ongoing commitment to innovation and a solid range of products creates a positive outlook for the stock.

RVTY has a solid range of products, which makes people feel positive about the stock.